SCHEDULE

APPROXIMATE area of the piece of land required to be taken: 10 acres. Being part Rural Section 11180, and being the whole of the land comprised and described in certificate of title, Volume 406, folio 240 (Canterbury Land Registry).

Situated in Block II, Waipara Survey District (Canterbury R.D.).

In the Canterbury Land District; as the same is more particularly delineated on the plan marked P.W.D. 135240, deposited in the office of the Minister of Works at Wellington, and thereon edged red.

As witness my hand at Wellington, this 3rd day of October 1951.

W. S. GOOSMAN, Minister of Works.

(P.W, 53/687, D.O. 37/99)

The Drug Tariff (September 1946) Amendment No. 13

PURSUANT to section 90 of the Social Security Act 1938, the PURSUANT to section 90 of the Social Security Act 1938, the Minister of Health hereby issues the following direction:—
1. (1) This direction may be cited as the Drug Tariff (September 1946), Amendment No. 13, and shall be read together with and deemed part of the Drug Tariff (September 1946),* (hereinafter referred to as the principal direction).

(2) This direction shall come into force on the 1st day of November 1951, except where otherwise specified.

2. Clause 4 of the principal direction is hereby amended as follows:—

follows :-

(a) By revoking the definition of the term "B.P.", and substituting the following definition:—
 ""B.P." means the 1948 edition of the British Pharmacopæia, together with the monographs set out in pages I to 71 inclusive of the Addendum 1951 to the British Pharmacopæia 1948:":
(b) By revoking the definition of the term "B.P.C.", and substituting the following definition:—
 ""B.P.C." means the general monographs in Part I and the preparations included in Part VI (the Formulary Section) of the British Pharmaceutical Codex 1949, together with amendments thereto in existence at the 1st day of September 1951."
3. The following materials are hereby added to the table of

3. The following materials are hereby added to the table of materials unconditionally excluded under paragraph (a) of clause 5 of the principal direction:—

Chloramphenicol (Chloromycetin),

Ointments, creams, and similar preparations containing Oestrone, Oestradiol Dipropionate, Oestradiol Benzoate, Ointments, creams, and similar preparations containing any antihistamine.

4. Part 1 of the Addendum dated September 1946, to the New Zealand Formulary is hereby amended by omitting the materials listed in the table of materials allowed under paragraph (b) of clause 5 of the principal direction, and substituting the following

Adrenaline Mucate for administration by injection,

Adrenaline Tartrate,

Antazoline Hydrochloride, Antazoline Hydrochloride, Antitoxin (Diphtheria), Antitoxin (Tetanus), Benedict's Solution (qualitative), Benzhexol Hydrochloride,

Calcium Aurothiomalate,

Chlorocyclizine Hydrochloride, Colloidal Calamine Comply

Complying with the standard defined in the New Zealand Formulary: Colloidal Kaolin Colloidal Zinc Oxide

Diethazine Hydrochloride,

Dihydroergotamine Methanesulphonate, Dihydrotachysterol or A.T. 10

Diphenylhydramine Hydrochloride,

Elixir of Diphenylhydramine Hydrochloride, Elixir of Diphenylhydramine Hydrochloride, Compound, Elixir of Mepyramine Maleate, Elixir of Promethazine Hydrochloride, Emulsifying Waxes and other similar agents as are approved from time to time by the Director-General of Health,

Ergometrine and its salts, Ethopropazine Hydrochloride, Extract of Ergot, Liquid, B.P. 1914,

Fehling's Solution Nos. 1 and 2, Globin Insulin,

Liver Extracts, including Vitamin B12 for administration by

injection, Mercuramide with Theophylline,

Mersalyl with Theophylline, Methaphenilene Hydrochloride, Methyl-cellulose,

Methylergotamine Tartrate, Mistura Aluminii Hydroxidi et Kaolini,

Oculentum Aureomycin,
Oculentum Ichthammol Compound, containing 2.5 per cent.
of Ichthammol with Zinc Oxide 2.5 per cent.,

Paramethadione,

Penicillin G diethylaminoethyl ester hydriodide Penicillin-Procaine and such preparations thereof as are approved from time to time by the Director-General of Health,

* Gazette, 30 January 1947, Vol. I, page 86.

Phenindamine Tartrate,

Pitressin Tannate in oil for injection,

Silver Picrate,

Compound powder of silver picrate 1 per cent. (with Kaolin),

Suppositories of silver picrate 2 per cent.,
Sulphanilamide, its salts, compounds, and derivatives of sulphanilamide, their salts, pursuant to any one medical prescription a supply sufficient for a period of seven days commencing on the date of presentation of the prescription commencing on the date of presentation of the prescription and when prescribed for external or topical application whether as an ointment, lotion, enema, suppository, or other similar preparation, a supply not exceeding a total quantity of 240 grains of one or more of the sulphonamides (whether supplied in powdered form or with a suitable vehicle). Compound sulphonamide suspension and such proprietary combinations containing sulphonamides as are approved from time to time by the Director-General of Health

Health,
Tablets of Magnesium Trisilicate and Dried Aluminium Hydrox-

ide Gel,
Tablets of Methoin,
Tablets of Methoin 0·10 G. with Phenobarbitone 0·02 G.,

Tablets of Phenytoin Sodium 11 grains with Phenobarbitone Sodium $\frac{2}{4}$ grain, Tablets of Thyroid (fresh gland) allowed only when specifically

prescribed, Thenylpyramine Hydrochloride, Thonzylamine Hydrochloride,

Tripelennamine Hydrochloride,
Troxidone, known also as Trimethadione,
Water soluble analogues of Vitamin K as are approved from
time to time by the Director-General of Health,
Such unofficial combinations of two or more pharmaceutical

requirements as are approved from time to time by the Director-General of Health.

5. Notwithstanding the provisions of clause 2 of this direction all materials which have been available at the cost of the Fund under the principal direction immediately before the commencement of this direction shall continue to be so available until the 31st day of

March 1952.

6. Clause 10 of the principal direction is hereby revoked, and the following clause substituted therefor:—

"10. (1) Notwithstanding anything contained in the last preceding clause, where in the opinion of the medical practitioner attending any patient no danger is involved in the use of a pharmaceutical requirement without medical supervision in the treatment of the following chronic conditions—namely, asthma, diabetes, ment of the following chronic conditions—namely, asthma, diabetes, epilepsy, hypothyroidism, pernicious anaemia, and such other conditions as are approved for this purpose from time to time by the Director-General of Health—a supply of that pharmaceutical requirement up to a quantity sufficient to supply that patient for a period not exceeding three months may be made, if the medical practitioner has endorsed a prescription therefor with the words 'Certified Extended Supply Condition,' together with the period for which the medication is to be supplied, not exceeding three months supply in respect of any one prescription supplied to the months supply in respect of any one prescription supplied to the

matter to concerned.

"(2) In any such case a contractor on receiving a medical prescription endorsed in accordance with subclause (1) of this clause may supply those pharmaceutical requirements and claim on the Fund accordingly."

7. The following materials are included under paragraph (b) of clause 5 of the principal direction subject to the condition that they are supplied by a Hospital Board approved by the Director-General of Health under conditions that are defined from time to time by the Director-General of Health:—

(a) Aureomycin,

Chloramphenicol (Chloromycetin). Hexamethonium Bromide (Vegolysen), Hexamethonium Iodide (Hexathide),

Hexamethonium Iodide (Hexathide),
Para-amino-salicylic acid and its salts,
Pentamethonium Bromide (Lytensium),
Pentamethonium Iodide (Antilussin).

(b) Such preparations of the materials mentioned in paragraph

(a) of this clause and such similar substances and preparations as are approved from time to time by the
Director-General of Health.

8. The table of authorized midwifery pharmaceutical requirements allowed under clause 14 of the principal direction is as follows :-

> Column 1. Description of Material.

Column 2. Maximum Quantity for One Patient.

Cyllin 4 oz. Dettol or Pynol or Streph 4 oz.

1 tube (not to be supplied with Dettol or Pynol or Streph). Dettol Cream

Iodine, weak tincture of 2 oz. Olive oil, or cotton-seed oil, or peanut oil 3 oz.

9. The following notices and directions are hereby revoked-

Date of Notice or Direction, No. 22 of 24 April 1947, at page 493, No. 59 of 9 October 1947, at page 1441. No. 61 of 3 November 1949, at page 2532. 8 April 1947 . . 7 October 1947 26 October 1949 No. 66 of 26 October 1950, at page 1897. No. 43 of 31 May 1951, at page 784. $26 \ {\rm October} \ 1950$ 29 May 1951 ... ٠..

Dated at Wellington, this 9th day of October 1951. J. R. MARSHALL, Minister of Health.